PRNewswire: August 29, 2016 – STANS, Switzerland, Aug. 29, 2016 – NLS Pharma Group (NLS) announced today that it has initiated enrollment for its “Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR)…
Business Wire: May 12, 2016 – PARIS, France, and STANS, Switzerland – NLS Pharma Group announced the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a phase IIb clinical trial with its lead compound Mazindol. The study is…
